AZN R&D to Revenue
AstraZeneca PLC Ordinary Shares · R&D to Revenue
AZN R&D to Revenue
Latest reported23.80%period ending
AZN Quarterly R&D/Revenue (0.00% → 23.80%)
Latest values, visible window
High-resolution chart · PNG
AZN r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 23.804% | |
| 22.8414% | |
| 24.9113% | |
| 24.113% | |
| 23.8985% | |
| 22.7333% | |
| 23.9809% | |
| 22.6318% | |
| 22.2291% | |
| 21.2872% | |
| 24.2432% | |
| 21.6411% | |
| 22.521% | |
| 21.1508% | |
| 22.5752% | |
| 21.5079% | |
| 22.6349% | |
| 19.2888% | |
| 19.929% | |
| 21.8224% | |
| 21.9221% | |
| 19.4765% | |
| 21.553% | |
| 21.944% | |
| 21.878% | |
| 20.54% | |
| 21.1675% | |
| 19.9729% | |
| 22.7718% | |
| 20.5128% | |
| 27.7693% | |
| 21.6981% | |
| 23.4249% | |
| 24.1792% | |
| 26.4324% | |
| 21.9673% | |
| 25.9553% | |
| 24.9584% | |
| 27.0546% | |
| 23.9165% | |
| 26.1467% | |
| 24.2028% | |
| 27.2855% | |
| 24.037% | |
| 23.244% | |
| 22.3873% | |
| 22.43% | |
| 23.7236% | |
| 20.5764% | |
| 18.7032% | |
| 20.8796% | |
| 13.728% | |
| 20.4589% | |
| 19.7181% | |
| 18.1269% | |
| 18.0186% | |
| 17.8529% | |
| 20.8192% | |
| 21.5689% | |
| 15.7799% | |
| 14.2112% | |
| 14.0135% | |
| 22.3976% | |
| 13.6364% | |
| 16.1409% | |
| 11.5555% | |
| 14.6898% | |
| 12.878% | |
| 13.3074% | |
| 12.7256% | |
| 17.9544% | |
| 16.2186% | |
| 15.8999% | |
| 15.3966% | |
| 17.9804% | |
| 18.5594% | |
| 16.4444% | |
| 16.7959% | |
| 15.7115% | |
| 14.7637% | |
| 14.4151% | |
| 13.932% | |
| 13.888% | |
| 13.4911% | |
| 14.0248% | |
| 15.0618% | |
| 21.2968% | |
| 15.6315% | |
| 16.7927% | |
| 16.89% | |
| 21.3744% | |
| 16.9034% | |
| 18.3701% | |
| 16.5153% | |
| 19.0121% | |
| 17.423% | |
| 16.7672% | |
| 15.7657% | |
| 17.4381% | |
| 15.5443% |